Regado Biosciences, which is focused on the discovery and development of drugs for cardiovascular indications, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The company is backed by founder of Fastenal and former Minnesota Senator, Robert Kierlin, who holds a 27% stake.
The Basking Ridge, NJ-based company, which was founded in 2001 and booked no revenue for the 2012 fiscal year, plans to list on the NASDAQ under the symbol RGDO. Regado Biosciences initially filed confidentially on 3/1/2013. Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
